Eton Pharmaceuticals rises after Q2 beat and FY26 revenue guidance
Eton Pharmaceuticals said second-quarter earnings were 43 cents a share versus the 10-cent consensus and sales were $37.568 million versus $27.119 million, while FY26 revenue guidance came in above estimates.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.